Pharmacotherapy of the 149 study patients
| Medication, No. (%) | Delayed enhancement | No delayed enhancement | p Value |
|---|---|---|---|
| HCTZ | 0 (0) | 7 (5) | >0.99 |
| ACE inhibitor or ARB | 2 (40) | 40 (28) | 0.62 |
| Loop diuretics | 0 (0) | 15 (10) | >0.99 |
| β-Blocker | 2 (40) | 78 (54) | 0.66 |
| CCB | 1 (20) | 26 (18) | >0.99 |
| Antiarrhythmic | 2 (40) | 62 (43) | >0.99 |
| Antiplatelet | 5 (100) | 134 (93) | >0.99 |
| Vasodilator | 0 (0) | 3 (2) | >0.99 |
| Potassium-sparing diuretics | 0 (0) | 10 (7) | >0.99 |
| Digoxin | 1 (10) | 7 (5) | 0.24 |
ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HCTZ, hydrochlorothiazide.